The stars weren't aligned

The stars weren't aligned

Buried in Carrington Laboratories' 10-Q was that the CARN was buying back its $6.6 million in convertible preferred shares sold in October. The company completed the transaction on May 21, for $7.8 million. CARN said it elected to spend the $1.2 million to save its common stockholders from dilution. The price tag for the repurchase includes CPA fees, attorney's fees registration fees and the like, according

Read the full 700 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers